1. CANVAS—CANagliflozin cardio Vascular Assessment Study (CANVAS).
https://clinicaltrials.gov/ct2/show/NCT01032629?term=NCT01989754&rank=2
.
2. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58).
https://clinicaltrials.gov/ct2/show/NCT01730534?term=NCT01730534&rank=1
.
3. Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004).
https://clinicaltrials.gov/ct2/show/NCT01986881?term=NCT01986881&rank=1
.
4. Zinman B, Wanner C, Lachin JM, et al. for the EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
5. Faillie JL. Pharmacological aspects of the safety of gliflozins. Pharmacol Res. 2016.
https://doi.org/10.1016/j.phrs.2016.07.001
.